Skip to main content
TipRanks
Go Ultimate75% OFF

Faes Farma (FAE) AI Stock Analysis

23 Followers
ES:FAE

Faes Farma

(BME:FAE)

Select Model
Rating:70Outperform
Price Target:EUR 5.50â–²(10.33% Upside)
Action:upgraded
Date:11/06/26

The overall score reflects a balanced profile. The company's consistent revenue growth and attractive valuation (low P/E, decent yield) are key strengths. These are tempered by significant margin pressure and weaker cash flow, likely tied to a recent acquisition. Technical trends are supportive, with the stock in a steady uptrend.

Positive Factors
Strong equity baseA sizable equity base provides resilience and supports continued investment in pharmaceuticals, manufacturing, and commercialization. Although leverage rose in 2025, the company enters this period with a history of conservative financing that can help absorb operational volatility and preserve strategic flexibility.
Negative Factors
Revenue and margin deteriorationThe 2025 reversal from prior revenue growth and strong margins creates a material near-term earnings risk that may persist over the next several quarters. Lower operating profit and net income reduce funds available for reinvestment and make sustained recovery dependent on restoring commercial momentum and profitability.

Faes Farma (FAE) vs. iShares MSCI Spain ETF (EWP)

-5%0%5%10%15%20%25%30%35%ES:FAE+9.95%EWP+19.17%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 1.55B
Dividend Yield
2.57%
Average Volume (3M)
170.71K
Price to Earnings (P/E)
11.5
Beta (1Y)
0.44
Revenue Growth
31.88%
EPS Growth
-20.09%
Country
Spain
Employees
2,677
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Faes Farma Business Overview & Revenue Model

Company Description

Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international...

How the Company Makes Money

Faes Farma makes money primarily by selling healthcare products, with revenue generated from: (1) Prescription pharmaceuticals: income from the commercialization of branded medicines and other prescription products sold through pharmaceutical distrib...

Faes Farma Financial Statement Overview

Summary

Faes Farma shows consistent revenue growth (~10% CAGR) and a solid balance sheet with moderate leverage (D/E 0.55). However, recent margin compression (gross margin fell to 37%) and weakened cash flow reduce the score from higher levels.

Income Statement

70Positive

Balance Sheet

75Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.04B610.46M493.65M451.17M438.75M398.56M
Gross Profit312.17M228.46M326.54M297.12M282.01M252.40M
EBITDA167.65M101.80M128.33M122.93M121.35M110.84M
Net Income136.19M79.63M111.36M91.90M89.50M82.39M
Balance Sheet
Total Assets1.44B1.34B853.08M776.03M725.67M641.76M
Cash, Cash Equivalents and Short-Term Investments136.78M130.09M72.14M47.75M84.10M73.41M
Total Debt396.85M409.91M7.79M23.90M32.69M16.44M
Total Liabilities664.48M594.19M126.46M112.68M123.39M103.70M
Stockholders Equity774.45M744.80M725.87M662.36M601.08M536.53M
Cash Flow
Free Cash Flow61.63M62.38M75.95M-1.22M25.84M20.23M
Operating Cash Flow79.45M78.49M115.47M100.97M106.79M79.64M
Investing Cash Flow-241.15M-299.02M-34.18M-97.36M-92.17M-83.48M
Financing Cash Flow182.02M273.62M-51.71M-35.38M-18.46M-17.12M

Faes Farma Technical Analysis

Technical Analysis SentimentPositive
Last Price4.99

Price Trends

50DMA4.76Positive
100DMA4.63Positive
200DMA4.66Positive

Market Momentum

MACD0.08Negative
RSI59.33Neutral
STOCH62.80Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:FAE, the sentiment is Positive. The current price of 4.99 is above the 20-day moving average (MA) of 4.87, above the 50-day MA of 4.76, and above the 200-day MA of 4.66, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 59.33 is Neutral, neither overbought nor oversold. The STOCH value of 62.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:FAE.

Faes Farma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ES:FAE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ES:NTHES:NTH81OutperformEUR 129.49M14.6752.07%11.74%-6.06%-15.89%
ES:GRFES:GRF75OutperformEUR 6.82B15.858.83%0.72%1.03%30.59%
ES:LOGES:LOG72OutperformEUR 4.87B17.3243.48%5.72%2.23%0.36%
ES:ALMES:ALM70OutperformEUR 2.29B30.744.81%1.78%9.67%174.00%
ES:FAEES:FAE70OutperformEUR 1.55B11.4618.19%2.57%31.88%-20.09%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ES:RJFES:RJF47NeutralEUR 214.90M30.813.14%0.74%-0.42%4.56%

* Healthcare Sector Average

Performance Comparison

-20%0%20%ES:FAEES:ALMES:GRFES:RJFES:LOGES:NTHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ES:FAE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ES:FAEFaes Farma4.990.5011.12%
ES:ALMAlmirall SA10.32-2.00-16.21%
ES:GRFGrifols (0RDU)11.411.3413.32%
ES:RJFLABORATORIO REIG JOFRE2.61-0.08-2.97%
ES:LOGCompania de Distribucion Integral Logista Holdings36.909.0132.31%
ES:NTHNaturhouse Health2.130.2311.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026